SIROLIMUS (RAPAMYCIN)

Rapamycin, originally identified as an antifungal macrolide antibiotic produced by Streptomyces hygroscopicus, is now primarily utilized for its potent immunosuppressive properties in the prevention of organ transplant rejection. The compound exerts its immunoregulatory effects by inhibiting the activation and proliferation of T lymphocytes. Mechanistically, Rapamycin binds to FK-binding protein 12 (FKBP12) to form the Rapamycin–FKBP12 complex, which subsequently modulates the mechanistic target of rapamycin (mTOR), a key kinase regulating cellular growth, metabolism, and progression through the cell cycle.

At lower, anti-aging–related dosing ranges, Rapamycin exhibits a distinct immunomodulatory profile characterized by the attenuation of hyperactive immune responses rather than broad immunosuppression. This functional modulation has been described as “immune rejuvenation,” enabling Rapamycin and its analog everolimus to act as immunostimulatory agents under specific physiological contexts. Empirical studies demonstrate that Rapamycin can reduce cytomegalovirus (CMV) incidence in transplant recipients, enhance anti-pathogen and antitumor immunity in murine models, extend lifespan in infection-prone mice, and confer protection against age-associated pulmonary infections. Additionally, Rapamycin exhibits antiviral activity by inhibiting viral replication, further broadening its therapeutic potential.

Active Ingredient
Rapamycin

Other ingredients
Microcrystalline cellulose

Rapamycin 2.5mg
2.5 mg Capsules – 30 count bottle

Rapamycin 5mg
5 mg Capsules – 30 count bottle